PureTech Health Past Earnings Performance
Past criteria checks 0/6
PureTech Health's earnings have been declining at an average annual rate of -59.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.4% per year.
Key information
-59.6%
Earnings growth rate
-59.9%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -14.4% |
| Return on equity | -29.4% |
| Net Margin | -17,620.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How PureTech Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -82 | 55 | 0 |
| 31 Mar 24 | 2 | -74 | 54 | 0 |
| 31 Dec 23 | 3 | -66 | 53 | 0 |
| 30 Sep 23 | 8 | -56 | 58 | 0 |
| 30 Jun 23 | 12 | -47 | 64 | 0 |
| 31 Mar 23 | 14 | -49 | 62 | 0 |
| 31 Dec 22 | 16 | -50 | 61 | 0 |
| 30 Sep 22 | 17 | -32 | 58 | -55 |
| 30 Jun 22 | 19 | -14 | 55 | 110 |
| 31 Mar 22 | 18 | -37 | 56 | 110 |
| 31 Dec 21 | 17 | -61 | 57 | 0 |
| 30 Sep 21 | 14 | -127 | 55 | 137 |
| 30 Jun 21 | 11 | -193 | 54 | 0 |
| 31 Mar 21 | 11 | -94 | 52 | 0 |
| 31 Dec 20 | 12 | 6 | 49 | 82 |
| 30 Sep 20 | 12 | 239 | 50 | 0 |
| 30 Jun 20 | 12 | 472 | 52 | 0 |
| 31 Mar 20 | 11 | 446 | 55 | 0 |
| 31 Dec 19 | 10 | 421 | 59 | 0 |
| 30 Sep 19 | 15 | 229 | 56 | 0 |
| 30 Jun 19 | 20 | 37 | 53 | 0 |
| 31 Mar 19 | 20 | -3 | 50 | 0 |
| 31 Dec 18 | 21 | -44 | 47 | 0 |
| 30 Sep 18 | 14 | 9 | 48 | 0 |
| 30 Jun 18 | 7 | 61 | 48 | 0 |
| 31 Mar 18 | 5 | 44 | 47 | 0 |
| 31 Dec 17 | 3 | 26 | 46 | 0 |
| 30 Sep 17 | 4 | -17 | 43 | -8 |
| 30 Jun 17 | 5 | -61 | 40 | -15 |
| 31 Mar 17 | 5 | -55 | 39 | -8 |
| 31 Dec 16 | 4 | -49 | 37 | 0 |
| 30 Sep 16 | 3 | -54 | 39 | 14 |
| 30 Jun 16 | 1 | -59 | 40 | 28 |
| 31 Mar 16 | 6 | -49 | 38 | 23 |
| 31 Dec 15 | 12 | -39 | 36 | 19 |
| 30 Sep 15 | 12 | -37 | 31 | 15 |
| 30 Jun 15 | 12 | -35 | 26 | 10 |
| 31 Mar 15 | 7 | -38 | 20 | 8 |
| 31 Dec 14 | 2 | -42 | 14 | 5 |
| 31 Dec 13 | 9 | -5 | 7 | 4 |
Quality Earnings: PRTCL is currently unprofitable.
Growing Profit Margin: PRTCL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRTCL is unprofitable, and losses have increased over the past 5 years at a rate of 59.6% per year.
Accelerating Growth: Unable to compare PRTCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTCL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: PRTCL has a negative Return on Equity (-29.38%), as it is currently unprofitable.